Gilead Sciences, Inc.
FXR (NR1H4) modulating compounds
Last updated:
Abstract:
The present disclosure relates generally to compounds that bind to FXR and act as agonists of FXR. The disclosure further relates to the use of the compounds for the preparation of a medicament for the treatment of diseases and/or conditions through binding of said nuclear receptor by said compounds and to a process for the synthesis of said compounds.
Status:
Grant
Type:
Utility
Filling date:
13 Jan 2020
Issue date:
18 Jan 2022